Pfizer will acquire Trillium Therapeutics Inc.; strengthening its work in oncology with the addition of next-generation, investigational immuno-therapeutics for hematological malignancies.
Locus Biosciences has signed a contract with BARDA to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage) that targets E. coli bacteria causing recurrent urinary tract infections (UTIs).
